plenvu dose 1 oral powder 115.96g sachets
forum health products ltd - sodium; potassium; chloride; macrogol '3350' - powder for oral solution - 321.8mmol/1litre ; 26.6mmol/1litre ; 95.2mmol/1litre ; 100gram
plenvu dose 2a oral powder 46.26g sachets
forum health products ltd - chloride; potassium; sodium; macrogol '3350' - powder for oral solution - 141.8mmol/1litre ; 32.2mmol/1litre ; 595.2mmol/1litre ; 40gram
plenvu dose 2b oral powder 55.65g sachets
forum health products ltd - sodium; ascorbic acid - powder for oral solution - 595.2mmol/1litre ; 7.54gram
dioralyte relief oral powder sachets blackcurrant
dendron brands ltd - sodium chloride; potassium chloride; sodium citrate; rice powder pre-cooked - powder for oral solution - 350mg ; 300mg ; 580mg ; 6gram
dioralyte relief oral powder sachets raspberry
dendron brands ltd - sodium chloride; potassium chloride; sodium citrate; rice powder pre-cooked - powder for oral solution - 350mg ; 300mg ; 580mg ; 6gram
cymalon 4g granules for oral solution sachets
teva uk ltd - sodium citrate - granules for oral solution - 4gram
kaletra oral solution
abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - solution (oral) - ritonavir 20 mg/ml; lopinavir 80 mg/ml - ritonavir - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.
kaletra oral solution
abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - solution (oral) - ritonavir 20 mg/ml; lopinavir 80 mg/ml - ritonavir - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.
olanzapine - olanzapine tablet, orally disintegrating
ajanta pharma limited - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 5 mg - oral olanzapine is indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13-17), efficacy was established in one 6-week trial [see clinical studies (14.1)] . when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia . clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions (5.5)] . monotherapy — oral olanzapine is indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy was established in three clinical trials in adult patients with man
aripiprazole oral solution 1mg/ml
liqmeds limited - aripiprazole - oral drops, solution - aripiprazole 1 milligram(s) - psycholeptics